Akebia Therapeutics (AKBA) Return on Sales: 2017-2025
Historic Return on Sales for Akebia Therapeutics (AKBA) over the last 8 years, with Sep 2025 value amounting to -0.07%.
- Akebia Therapeutics' Return on Sales fell 319.00% to -0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.07%, marking a year-over-year decrease of 319.00%. This contributed to the annual value of -0.43% for FY2024, which is 476.00% up from last year.
- Per Akebia Therapeutics' latest filing, its Return on Sales stood at -0.07% for Q3 2025, which was up 60.54% from -0.18% recorded in Q2 2025.
- Akebia Therapeutics' 5-year Return on Sales high stood at 3.99% for Q2 2024, and its period low was -16.54% during Q1 2024.
- Its 3-year average for Return on Sales is -1.51%, with a median of -0.25% in 2025.
- In the last 5 years, Akebia Therapeutics' Return on Sales crashed by 1,632bps in 2024 and then spiked by 1,629bps in 2025.
- Akebia Therapeutics' Return on Sales (Quarterly) stood at -1.34% in 2021, then surged by 99bps to -0.35% in 2022, then slumped by 484bps to -5.19% in 2023, then soared by 476bps to -0.43% in 2024, then plummeted by 319bps to -0.07% in 2025.
- Its last three reported values are -0.07% in Q3 2025, -0.18% for Q2 2025, and -0.25% during Q1 2025.